Advertisement
Advertisement
PRLD
Prelude Therapeutics Incorporated
3.60
USDSponsored
+0.04
+1.27%
Nov 06, 15:59 UTC -5
Closed
After-Market
3.65
+0.05
+1.39%
Prelude Therapeutics Incorporated (PRLD) Earnings
PRLD Earnings Reports
Positive Surprise Ratio
PRLD beat 17 of 24 last estimates.
71%
Next Report
Tomorrow
Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
$29.58M
/$0.03
Implied change from Q2 26 (Revenue/ EPS)
+418.58%
/-121.43%
Implied change from Q3 25 (Revenue/ EPS)
+355.08%
/-111.54%
Prelude Therapeutics Incorporated earnings per share and revenue
On Aug 11, 2026, PRLD reported earnings of -0.14 USD per share (EPS) for Q2 26, beating the estimate of -0.20 USD, resulting in a 30.21% surprise. Revenue reached 5.70 million, compared to an expected --, with a 0.00% difference. The market reacted with a +10.14% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of 0.03 USD, with revenue projected to reach 29.58 million USD, implying an decrease of -121.43% EPS, and increase of 418.58% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cronos Group Inc. Common Share
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
Aclaris Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.12
Surprise
+28.49%
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
Minerva Neurosciences, Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.12
Actual
$1.94
Surprise
+1,629.97%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.25
Surprise
-40.06%
ZOETIS INC.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.52
Actual
$1.75
Surprise
+14.64%
Dyne Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.92
Actual
-$1.06
Surprise
-15.57%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.38
Surprise
+1.04%
Aldeyra Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+37.43%
Lipocine Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.08
Surprise
+77.91%
FAQ
What were Prelude Therapeutics Incorporated's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Prelude Therapeutics Incorporated reported EPS of -$0.14, beating estimates by 30.21%, and revenue of $5.70M, 0% as expectations.
How did the market react to Prelude Therapeutics Incorporated's Q2 2026 earnings?
The stock price moved up 10.14%, changed from $4.83 before the earnings release to $5.32 the day after.
When is Prelude Therapeutics Incorporated expected to report next?
The next earning report is scheduled for Nov 10, 2026.
What are the forecasts for Prelude Therapeutics Incorporated's next earnings report?
Based on 5
analysts, Prelude Therapeutics Incorporated is expected to report EPS of $0.03 and revenue of $29.58M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.